Navigation Links
Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
Date:5/9/2011

THE WOODLANDS, Texas, May 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it will hold its Annual R&D Day on Thursday, May 12, 2011 from 9:00 a.m. to 12:00 p.m. Eastern Time in New York, New York.  Members of Lexicon's senior management team will provide in-depth reviews of the company's clinical programs and an overview of several other preclinical programs in the company's pipeline.  The review of the company's clinical programs will include a presentation of results obtained to date from carcinoid syndrome patients participating in the E.U.-based open-label clinical trial of LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels.

A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com.  An archived version of the webcast will be available for 30 days after the event on the company's website.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "f
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced ... Global Industry Analysis, Size, Share, Growth, Trends And Forecast, ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... patients in order to treat dental impairments, for tooth ...
(Date:1/15/2014)... AARP Foundation today announced it has established a relief ... cold weather that has gripped much of the nation. AARP ... so to support these emergency relief efforts AARP and AARP ... mean up to $500,000 in aid. The matching program will ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... 9, 2012 SciVerse Hub, SciVerse Applications, ... Sciences Recognized for Innovation and Achievement ... medical information products and services, today announced that it ... American Publishers Awards for Professional and Scholarly Excellence (the ...
... SAN DIEGO, Feb. 9, 2012  Volcano Corporation (NASDAQ: ... precision guided therapy tools designed to enhance the diagnosis ... announced it will report its operating results for the ... The company will hold a conference call ...
Cached Medicine Technology:Elsevier Honored With Six PROSE Awards 2Elsevier Honored With Six PROSE Awards 3Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast 2
(Date:7/9/2014)... Health Organization recommends that youth participate in a minimum ... (MVPA) each day. Studies have shown that youth ... Therefore, it stands to reason that increasing outdoor time ... new study scheduled for publication in The Journal ... after school was positively associated with MVPA. , Drs. ...
(Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
(Date:7/9/2014)... of lung cancer, researchers have uncovered mutations in a ... The new knowledge may expand treatments for patients because ... available or are in clinical trials. , Reporting July ... Genome Atlas (TCGA), including researchers at Washington University School ... other institutions, studied tumors from 230 patients with lung ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... July 9, 2014 There has been a sharp ... Southwestern Medical Center using MyChart, the online, interactive service ... communicate with their healthcare providers, schedule appointments, and renew ... patients actively using MyChart each year increased ... increased more than 10-fold, according to a study by ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3
... , LYNBROOK, N.Y., Sept. 16 ... a biopharmaceutical company developing first-in-class collagenase-based products, today announced ... Food and Drug Administration,s (FDA) unanimously recommended by a ... histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing ...
... published online today [Thursday] estimates nearly 45,000 annual deaths are ... two and a half times higher than an estimate from ... study, "Health Insurance and Mortality in U.S. Adults," appears in ... Public Health . The Harvard-based researchers found that uninsured, ...
... , SAN FRANCISCO, Sept. 21 Medithrive, Inc., ... its state of the art dispensary, offering patients a beautiful ... of medicinal marijuana products. , , ... 16th, in San Francisco, CA, has positioned itself as the ...
... post-menopausal women with early breast cancer to the drug exemestane ... keeping them on tamoxifen for five years improves the chance ... for at least the next six years. "These ... mid-way through the five-year tamoxifen treatment plan provides a clear ...
... CINCINNATICancer predisposition resulting from the presence of a ... researchers at the University of Cincinnati (UC) have ... risk for development of cancer in individuals harboring ... a result of environmental exposure. Peter Stambrook, PhD, ...
... NEW YORK, Sept. 21 In a bid ... online auction of the Ysio Digital Radiology System. As the ... N.Y., presented them a check for $285,309. , , ... , http://inr.mediaseed.tv/oneClip_C/?feed=hK4UKEtcAILqy08qpCX6wBwEMnTvqjZg , , ...
Cached Medicine News:Health News:FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytren's Disease 2Health News:FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytren's Disease 3Health News:45,000 excess deaths annually linked to lack of health insurance: Harvard study 2Health News:Switching early breast cancer patients to exemestane improves long-term survival 2Health News:Cancer predisposition from genetic variation shows strong gender bias 2
... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
... Our most popular onsite test! QuickScreen™ ... the urine sample, and your choice of ... QuickScreen™ multi-panels offer total flexibility for your ... into the specimen and the built-in timer ...
... products, SEDIPLAST® is a completely closed ... protect laboratory personnel from the risk ... a uniquely designed erythrocyte sedimentation rate ... and convenience as well as reliable ...
... guaiac as a test for the presence of ... compounds present in guaiac to quinones, resulting in ... is present, the heme portion of the hemoglobin ... the release of oxygen from hydrogen peroxide which ...
Medicine Products: